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EDITORIAL COMMENT
The Less Familiar
Face of Heart Failure*
Mariell Jessup, MD, FACC
Philadelphia, Pennsylvania
Nearly five million Americans have heart failure (HF)
today, an incidence approaching 10 per 1,000 population
after the age of 65 years. Heart failure is the reason for at
least 20% of all hospital admissions in persons above the age
of 65 years; hospitalizations for HF have increased by 159%
(1). Substantial efforts have been made to identify and treat
those factors that predict recurrent hospitalization for HF,
in addition to the identification of therapies that improve
overall survival. Indeed, over the past decade, multiple
clinical trials have unequivocally demonstrated a significant
reduction in mortality for patients with systolic HF. Simul-
taneously, however, large epidemiologic or cohort registries
have not observed an equivalent impact on overall death
rates from HF (2–4). Clearly, as has been noted by a
number of investigators, the patients entered into recent
clinical trials of HF have not been entirely representative of
the “typical” patient with HF in the U.S. (5).
See page 217
It is in the context of a further description of patients with
HF who are utilizing our hospitals that the study by
Masoudi et al. (6) in this issue of the Journal is of great
interest. They abstracted charts from 37,500 Medicare
beneficiaries hospitalized primarily for HF from the Na-
tional Heart Failure Project (NHF) database. They report
three important observations.
1. Only 57% of patients had an assessment of left ventric-
ular function to determine ejection fraction (EF) during
their index hospitalization. Guidelines for the manage-
ment of HF have outlined the need for a measurement of
ventricular function since 1994 (7).
2. Of the 19,710 patients with a documented EF, 66% had
HF associated with systolic dysfunction. Approximately
a third of all patients had HF with a preserved EF (an
EF of 50% in this study), a syndrome that has been
termed diastolic HF (8,9).
3. Diastolic HF was present almost twice as frequently in
women as in men. This correlation was consistent across
a wide range of patient characteristics, including age and
etiology of cardiac disease.
These investigators are not the first to report the higher
prevalence of diastolic HF in elderly women, as the authors
acknowledge in their discussion. Likewise, the incidence of
diastolic HF in hospitalized patients is also not a new
observation. However, this analysis comprises a several-fold
higher number of patients than previous studies, and Ma-
soudi et al. (6) have attempted to eliminate potential flaws
or biases of previous, smaller studies.
There are a number of implications in these data, some of
which have been emphasized by the authors. Table 1 depicts
the age and gender characteristics of some representative
cardiovascular trials, the majority of which were multicenter,
randomized studies involving patients with systolic dysfunc-
tion (10–18), with or without (19–22) symptomatic HF.
Other studies depicted in Table 1 examine the cause of
unexplained cardiomyopathy (23), or those factors that best
predict survival after the onset of HF (24). Two pivotal trials
examining the impact of intervention in high-risk popula-
tions with vascular disease or acute coronary syndromes are
also included (25,26). The mean age of the populations
studied was usually 65 years, and women were typically
underrepresented. (The number of women from races other
than Caucasian is not usually reported.) Even in trials
structured to investigate the response of an older population
(14), or in cardiovascular syndromes such as aortic stenosis
(27), often associated with elderly women, fewer than half of
the participants were female. It is only in the large
population-based studies that the natural history of the
elderly and women has been explored (2,4,28–30).
Is there any reason to think that elderly patients or
women respond differently to therapy for HF? Several
studies in Table 1 noted a prognostic impact of age, so that
clinical outcome worsened as patients advanced in years
(4,23,27). The impact of age on decisions to proceed with
thrombolysis or catheter-based intervention after myocar-
dial infarction has become important as a result of clinical
trials including very elderly patients. Management algo-
rithms for patients with cardiomyopathy, with or without
symptoms, may also need to consider age as a valuable
determinant, especially when the cost of defibrillators or
ventricular assist devices may be applied. Elderly patients
tend to have a higher prevalence of comorbidities, and an
increased incidence of adverse effects to medications, in
addition to the altered pathophysiology of the aging myo-
cardium and conduction system (31–33).
A growing body of literature suggests that there are
gender differences in the biologic response to chronic
hypertension, pressure overload such as seen in aortic
stenosis, and myocyte loss after myocardial infarction (34).
Hypertension and diabetes seem to confer a greater risk of
HF for women compared to men, despite the usual finding
of less coronary disease in females (35). Conclusive data for
the reduction of mortality and morbidity after angiotensin-
converting enzyme inhibition exist only for men with HF;
beta-blockers appear to be effective for both genders with
systolic dysfunction and symptoms of HF (36). Everything
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the Heart Failure/Transplant Program, Cardiovascular Disease, Department
of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Journal of the American College of Cardiology Vol. 41, No. 2, 2003
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Science Inc. PII S0735-1097(02)02697-9
Table 1. Age and Gender Characteristics of Representative Heart Failure or Cardiovascular Trials





SOLVD, 1991 (19) ACEI in HF; mortality 2,569 61 20% no gender or age difference observed in primary result
PROMISE, 1991 (10) Oral inotrope in HF; mortality 1,088 64 22% no gender or age difference observed in primary result
DIG, 1997 (11) Digoxin in HF; mortality 6,800 63 22% no gender or age effect on primary outcome
RALES, 1999 (12) spironolactone in HF; mortality 1,663 65 27% no gender or age difference observed in primary result
ATLAS, 1999 (13) Dose effect of ACEI in HF; mortality 3,164 64 20% gender or age effect not reported
ELITE II, 2000 (14) ARB versus ACEI in HF; mortality 3,152 72 30% no gender or age difference observed in primary result
Unexplained Cardiomyopathy, 2000
(23)
Examine cause of new onset HF 1,230 48 40% female gender had better prognosis overall; increasing
age had worse prognosis
Val-HeFT, 2001 (15) ARB in HF; mortality 5,010 63 20% no gender or age difference observed in primary result
BEST, 2001 (16) Beta-blocker in HF; mortality 2,708 60 22% no gender difference in primary outcome; age effect
not reported
COPERNICUS, 2001 (17) Beta-blocker in HF; mortality 2,289 63 20% no gender or age difference observed in primary result
CIBIS II, 2001 (18) Beta-blocker in HF; mortality 2,647 Women—65;
men—60
19% female gender had better prognosis; increasing age
had worse prognosis
HFSS Score, 1997 (24) Risk stratification in HF 467 51 20% gender or age not important in risk profile
STAT-CHF, 1995 (20) Amiodarone in HF and PVCs; mortality 674 65 1% gender or age effect not reported
CABG Patch, 1997 (21) ICD in EF  36% at CABG, abnormal signal
average; mortality
1,055 64 16% gender or age effect not reported
Outcome in Aortic Stenosis, 2000 (27) Predictors of outcome in severe, asymptomatic
AS
128 60 45% no gender effect on outcome; increasing age had
worse prognosis
HOPE, 2000 (26) ACEI in vascular disease  diabetes;
composite
9,297 66 27% no gender or age effect on primary outcome
MIRACL, 2001 (25) Statin after ACS; composite 3,086 65 35% no gender or age effect on primary outcome
CAT, 2002 (22) ICD in EF  30%; mortality 104 52 20% no gender or age effect on primary outcome
Strong Heart Study, 2000 (28) Prevalence of DHF 3,638 62 64% DHF more often in older women
Scotland population, 2000 (4) Mortality in hospitalized patients with all
CHF
66,547 75 53% age and gender had impact on mortality
Testing in DHF, 2001 (30) Clinical utility of EF 63 58 35%
Framingham Heart, 2002 (29) Risk of hypertension 1,298 Baseline: 55–65 54% no effect of age or gender on risk
ACEI angiotensin-converting enzyme inhibitor; ACS acute coronary syndrome; ARB angiotensin receptor blockade; AS aortic stenosis; CHF both systolic and diastolic dysfunction leading to heart failure; CABG coronary










from apoptosis to arrhythmias appears to exhibit gender-
specific characteristics.
If diastolic HF is often a disease of elderly women (8,9),
and we have little information acquired from clinical trials
to date about the elderly or about women, it should not be
unexpected that there is a mounting sense of urgency to
become more familiar with this group of patients (37). To
make a meaningful dent in the cost to our economy from
HF admissions, we are obligated to begin clinical trials in
patients with diastolic HF. Federal efforts to increase the
representation of women in clinical trials have been mod-
erately successful, primarily because of a small number of
large, single-gender trials involving coronary disease. There
has been little change in the gender composition of cohorts
in the majority of other studies of cardiovascular disease
(38). This could change dramatically if we started to enroll
subjects in a trial on diastolic HF.
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